Most of the studies and clinical trials evaluate the efficacy and safety of SGLT2-i by enrolling patients affected by long-term diabetes with high cardiovascular risk, while no studies have been conducted on the impact of SGLT2-i on recent diagnoses and low cardiovascular risk. Here, SLC5A2 is linked to diabetes mellitus.